Objective
Tumour immune-therapy has made dramatic improvements in recent years, saving the lives of cancer patients who just a
few years ago would have been considered untreatable. It thereby became apparent that one specific type of immune cell,
so called regulatory T-cells, critically hampers the efficacy of tumour immune-therapy. Tumours, however, attract and exploit
the immune-regulatory function of Tregs to dampen local immune responses and to induce local tolerance.
In recent years, inhibitors that directly target immune-suppressive mechanisms of T cells have found clinical application with
great success. The clinical application of these so called “check-point inhibitors”, however, is accompanied by severe side
effects in treated patients. Thus improvement of the efficacy of current immune-therapeutic treatments is a major unmet
need. This proposal will employ the newest developments in antibody design to target the next generation of biologics right
towards tumour-residential Tregs or directly into the tumour micro-environment itself. In this way we will be able to
specifically shift the local immune suppressive environment within tumours, while leaving tissue homeostasis in noncancerous
tissues unaffected, and thus diminish treatment associated side-effects.
The here proposed project combines the expertise of fundamental immunologist, tumour immunologists and cell biologists
with that of a life-science biotechnology company and that of experts in clinical cancer research to address this aspect. This
group will lead a training network that aims at educating a new generation of researchers, who will be able to bridge the
innovation gap between, on the one hand, early discoveries in tumour-immunology as well as in antibody technology and, on
the other hand, the efficient translation and clinical validations of these findings in patients.
Fields of science
Programme(s)
Funding Scheme
MSCA-ITN-EID - European Industrial DoctoratesCoordinator
31080 Pamplona
Spain
See on map
Participants (5)
EH8 9YL Edinburgh
See on map
Participation ended
5349 AB Oss
31008 Pamplona
See on map
20009 San Sebastian
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
3584 CS Utrecht
See on map
Partners (2)
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
2333 ZA Leiden
See on map
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
79108 Freiburg
See on map